#solidbiosciences
LightNews LightNews
dmdwarrior.com
Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #gene #dna #solidbiosciences #sgt003
Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy Solid Biosciences shared detailed information about the clinical trials of its SGT-003 Gene Therapy developed for the treatment of Duchenne Muscular Dystrophy. Solid Biosciences shared that four patients have been dosed in the SGT-003 gene therapy clinical trial; it was well tolerated in all patients with no side effects observed; and data from the first three patients could be available in Q1 2025.
January 16, 2025 at 9:22 AM
dmdwarrior.com
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #solidbiosciences #mayoclinic
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
December 5, 2024 at 12:06 PM
theakarifoundation.bsky.social
Solid Biosciences comparte actualización sobre SGT-003, su terapia génica en investigación. 

🔗Lee el artículo completo en el link: https://theakarifoundation-pr.org/solid-biosciences-comparte-una-actualizacion-sobre-sgt-003-su-terapia-genica-en-investigacion/

#TheAkariFoundation #SolidBiosciences
July 2, 2026 at 3:31 PM
theakarifoundation.bsky.social
🔗Lee el artículo completo en el link: https://theakarifoundation-pr.org/solid-biosciences-administra-dosis-al-primer-participante-del-ensayo-clinico-de-fase-3-impact-duchenne-el-cual-evalua-la-terapia-sgt-003-en-la-distrofia-muscular-de-duchenne/

#TheAkariFoundation #DMD #SolidBiosciences
June 4, 2026 at 3:33 PM
theakarifoundation.bsky.social
De acuerdo con Solid, a 33 participantes se les ha administrado la dosis en el ensayo clínico de Fase 1/2 INSPIRE DUCHENNE de la terapia SGT-003.👥🔬

🔗Lee el artículo completo en el siguiente link: lnkd.in/eHCh9s6i

#TheAkariFoundation #DistrofiaMuscularDeDuchenne #SolidBiosciences
February 5, 2026 at 2:54 PM